Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

Emerging evidence suggests that immunological responses to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients are attenuated, with reported seroconversion rates of less than 60%. However, there are insufficient data on responses to adenoviral vector SARS-CoV-2 vaccines in transplant populations. Here we describe immunological responses to two-dose vaccination with BNT162b2 (Pfizer–BioNTech) and ChAdOx1 (Oxford University–AstraZeneca) in kidney transplant recipients.

Author list


Maria Prendecki

Tina Thomson

Candice L Clarke

Paul Martin

Sarah Gleeson

Rute Cardoso De Aguiar

Helena Edwards

Paige Mortimer

Stacey McIntyre

Donald Mokreri

Alison Cox

Graham Pickard

Liz Lightstone

David Thomas

Stephen P McAdoo

Peter Kelleher

Michelle Willicombe

the Imperial Renal COVID-19 vaccine study group in collaboration with the OCTAVE Study Consortium


Novel Coronavirus SARS-CoV-2


The Lancet